NASDAQ:LEXX Lexaria Bioscience Q4 2026 Earnings Date & Estimates $3.27 -0.05 (-1.51%) Closing price 10/12/2026 03:59 PM EasternExtended Trading$3.26 -0.02 (-0.46%) As of 10/12/2026 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexaria Bioscience is estimated to report Q4 2026 earnings on Wednesday, October 28, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ4 2026Announcement DateOctober 28, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Lexaria Bioscience in Q4 2026Lexaria Bioscience is expected to post earnings of -$0.90 per share on revenue of $0.05 million. Lexaria Bioscience last reported on July 13, 2026, posting -$0.08 per share and missing the -$0.06 consensus estimate. Lexaria Bioscience has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.90Expected Revenue$0.05 millionRecent Track RecordLast ReportedQ3 2026Last Quarter EPS-$0.08 (Missed by -$0.02)EPS Beat Rate3 of last 8 quartersPrepare for the Q4 2026 CallEarnings HistoryCompany ProfileQ3 2026 Earnings ReportQ2 2026 Earnings ReportQ1 2026 Earnings Report Lexaria Bioscience Q4 2026 Earnings FAQ When does Lexaria Bioscience report Q4 2026 earnings? Lexaria Bioscience (NASDAQ:LEXX) is estimated to report Q4 2026 earnings on Wednesday, October 28, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Lexaria Bioscience's Q4 2026 earnings call? Lexaria Bioscience's Q4 2026 earnings conference call is scheduled for Tuesday, November 24, 2026 at 12:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Lexaria Bioscience? Analysts expect Lexaria Bioscience to post earnings of -$0.90 per share for Q4 2026. How much revenue is Lexaria Bioscience expected to report? The consensus revenue estimate for Lexaria Bioscience is $0.05 million for Q4 2026. Lexaria Bioscience Earnings HeadlinesWall Street Zen Upgrades Lexaria Bioscience (NASDAQ:LEXX) to "Sell"October 10 at 1:31 AM | americanbankingnews.comLexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsSeptember 9, 2026 | finanznachrichten.deThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)LEXX: Introducing DehydraTECH 3.0September 8, 2026 | finance.yahoo.comLexaria Bioscience advances 12% on Australian tax rebateSeptember 1, 2026 | seekingalpha.comLexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14%September 1, 2026 | msn.comSee More Lexaria Bioscience Headlines About Lexaria BioscienceLexaria Bioscience (NASDAQ:LEXX) (NASDAQ:LEXX) is a biotechnology company developing drug-delivery technologies designed to improve the way active pharmaceutical and nutritional compounds are absorbed and used by the body. Its principal technology, DehydraTECH, is intended to enhance the delivery, bioavailability, and performance of orally administered compounds. The company has investigated DehydraTECH applications involving cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, antiviral compounds, and other active ingredients. Lexaria’s work includes formulation development, laboratory research, and human and animal studies aimed at evaluating the technology’s potential across pharmaceutical, wellness, and consumer products. Lexaria is based in Kelowna, British Columbia, Canada, and conducts research and business activities through its corporate operations and commercial relationships. The company has historically focused on developing and protecting its intellectual property, with the potential to license or commercialize DehydraTECH-enabled products. Chris Bunka has served as the company’s chief executive officer and chairman.View Lexaria Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
